Advertisement

Hormones

, Volume 16, Issue 2, pp 139–149 | Cite as

Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review

  • Mussa H. Almalki
  • Nora Nasser Aljoaib
  • Maha Jurais Alotaibi
  • Bayan Saloum Aldabas
  • Tayba Saleh Wahedi
  • Maswood M. Ahmad
  • Fahad Alshahrani
Review

Abstract

Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern. Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to other therapies. To date, no control trials have been undertaken and only single case reports of pituitary tumors treated with TMZ have been published. A systematic literature search was conducted for studies reporting the use of TMZ for the treatment of prolactinomas that were resistant to standard therapy. In total, 42 reported cases were identified and included in our analysis: 23 cases of prolactin-secreting adenomas and 19 of prolactin-secreting carcinomas. Prior to TMZ administration, patients had exhibited tumor progression and had previously undergone various treatments including surgery, radiotherapy, and drug therapy. Tumor shrinkage was reported in 76% of patients. Reduced prolactin levels were observed in 75% of patients, while normalization of prolactin was reported in 8%. TMZ failure occurred in 20.6% of cases. Most patients exhibited no serious adverse effects. In conclusion, TMZ has potential for the treatment of highly aggressive and resistant prolactin-secreting adenomas and carcinomas, as demonstrated by tumor shrinkage or complete response and normalization of hormone hypersecretion, and exhibits good tolerability and few side effects.

Key words

Bromocriptine Cabergoline Dopamine agonist Prolactinoma Resistance Temozolomide 

References

  1. 1.
    Fadul CE, Kominsky AL, Meyer LP, et al, 2006 Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105: 621–626.CrossRefGoogle Scholar
  2. 2.
    Gillam MP, Molitch ME, Lombardi G, Colao A, 2006 Advances in the treatment of prolactinomas. Endocr Rev 27: 485–534.CrossRefGoogle Scholar
  3. 3.
    Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M, 2009 Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161: 631–637.CrossRefGoogle Scholar
  4. 4.
    Maiter D, Delgrange E, 2014 Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170: R213–227.CrossRefGoogle Scholar
  5. 5.
    DeLellis RA, Lloyd R, Heitz PU, (eds) 2004 WHO Classification of Tumors, Pathology and Genetics: Tumors of Endocrine Organs. Lyon, France: IARC Press.Google Scholar
  6. 6.
    Oh MC, Aghi MK, 2011 Dopamine agonist-resistant prolactinomas. J Neurosurg 114: 1369–1379.CrossRefGoogle Scholar
  7. 7.
    Melmed S, Casanueva FF, Hoffman AR, et al, 2011 Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96: 273–288.CrossRefGoogle Scholar
  8. 8.
    Jaffrain-Rea ML, 2014 From resistant to aggressive and malignant prolactinomas: A translational approach. J Endocr Disord 1: 1012.Google Scholar
  9. 9.
    Lim S, Shahinian H, Maya MM, Yong W, Heaney AP, 2006 Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7: 518–520.CrossRefGoogle Scholar
  10. 10.
    Moisi M, Cruz AS, Benkers T, Rostad S, 2016 Treatment of aggressive prolactin-secreting pituitary adenomas with adjuvant temozolomide chemotherapy: A review. Cureus 8: e658.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Bengtsson D, Schrøder HD, Andersen M, et al, 2015 Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100: 1689–1698.CrossRefGoogle Scholar
  12. 12.
    Strowd RE, Salvatori R, Laterra JJ, 2015 Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. J Oncol Pharm Pract 0: 1–6.Google Scholar
  13. 13.
    Murakami M, Mizutani A, Asano S, et al, 2011 A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma. Neurosurgery 68: 1761–1767.CrossRefGoogle Scholar
  14. 14.
    Bruno OD, Juarez-Allen L, Christiansen SB, et al, 2015 Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from Argentina. Int J Endocrinol 2015: 587–893.CrossRefGoogle Scholar
  15. 15.
    Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, François P, 2013 Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16: 515–522.CrossRefGoogle Scholar
  16. 16.
    Hirohata T, Asano K, Ogawa Y, et al, 2013 DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98: 1130–1136.CrossRefGoogle Scholar
  17. 17.
    Philippon M, Morange I, Barrie M, et al, 2012 Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Ann Endocrinol (Paris) 73: 225–229.CrossRefGoogle Scholar
  18. 18.
    Whitelaw BC, Dworakowska D, Thomas NW, et al, 2012 Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76: 877–886.CrossRefGoogle Scholar
  19. 19.
    Phillips J, East HE, French SE, Melcescu E, et al, 2012 What causes a prolactinoma to be aggressive or to become a pituitary carcinoma? Hormones (Athens) 11: 477–482.CrossRefGoogle Scholar
  20. 20.
    Whitelaw BC, Dworakowska D, Thomas NW, et al, 2012 Temozolomide treatment of a resistant prolactinomas. Clin Endocrinol (Oxf) 76: 877–886.CrossRefGoogle Scholar
  21. 21.
    Raverot G, Sturm N, de Fraipont F, et al, 2010 Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95: 4592–4599.CrossRefGoogle Scholar
  22. 22.
    Bush ZM, Longtine JA, Cunningham T, et al, 2010 Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95: E280–290.CrossRefGoogle Scholar
  23. 23.
    Byrne S, Karapetis C, Vrodos N, 2009 A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 16: 1694–1696.CrossRefGoogle Scholar
  24. 24.
    McCormack AI, McDonald KL, Gill AJ, et al, 2009 Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71: 226–233.CrossRefGoogle Scholar
  25. 25.
    Kovacs K, Horvath E, Syro LV, et al, 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38: 185–189.CrossRefGoogle Scholar
  26. 26.
    Debono M, Bridgewater C, Ross R, Newell-Price J, 2008 Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response to temozolomide. Endocrine Abstracts 15: P188.Google Scholar
  27. 27.
    Neff LM, Weil M, Cole A, et al, 2007 Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10: 81–86.CrossRefGoogle Scholar
  28. 28.
    Losa M, Mazza E, Terreni MR, McCormack A, et al, 2010 Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163: 843–851.CrossRefGoogle Scholar
  29. 29.
    Knizhnik AV, Roos WP, Nikolova T, et al, 2013 Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One 8: e55665.CrossRefGoogle Scholar
  30. 30.
    Bello MJ, De Campos JM, Isla A, Casartelli C, Rey JA, 2006 Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8. Oncol Rep 15: 443–448.PubMedGoogle Scholar
  31. 31.
    Martin SA, Lord CJ, Ashworth A, 2010 Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 16: 5107–5113.CrossRefGoogle Scholar
  32. 32.
    Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M, 2007 Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60: 993–1004.CrossRefGoogle Scholar
  33. 33.
    Liu JK, Patel J, Eloy JA, 2015 The role of temozolomide in the treatment of aggressive pituitary tumors. J Clin Neurosci 22: 923–929.CrossRefGoogle Scholar
  34. 34.
    Syro LV, Ortiz LD, Scheithauer BW, et al, 2011 Treatment of pituitary neoplasms with temozolomide: a review. Cancer 117: 454–462.CrossRefGoogle Scholar
  35. 35.
    Syro LV, Uribe H, Penagos LC, et al, 2006 Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65: 552–553.CrossRefGoogle Scholar
  36. 36.
    Khasraw M, Bell D, Wheeler H, 2009 Long-term use of temozolomide: could you use temozolomide for life in gliomas? J Clin Neurosci 16: 854–855.CrossRefGoogle Scholar
  37. 37.
    Raverot G, Burman P, McCormack A, et al, Clinical practice guideline for the management of aggressive pituitary tumors and carcinomas. (In press).Google Scholar

Copyright information

© Hellenic Endocrine Society 2017

Authors and Affiliations

  • Mussa H. Almalki
    • 1
    • 2
  • Nora Nasser Aljoaib
    • 3
  • Maha Jurais Alotaibi
    • 3
  • Bayan Saloum Aldabas
    • 3
  • Tayba Saleh Wahedi
    • 1
  • Maswood M. Ahmad
    • 1
  • Fahad Alshahrani
    • 4
  1. 1.Obesity, Endocrine, and Metabolism CenterKing Fahad Medical CityRiyadhKingdom of Saudi Arabia
  2. 2.King Fahad Medical City, College of MedicineKing Saud bin Abdulaziz University for Health ScienceRiyadhSaudi Arabia
  3. 3.Almareefa College for Science and Technology (MCST)RiyadhSaudi Arabia
  4. 4.King Abdulaziz Medical City, College of MedicineKing Saud bin Abdulaziz University for Health ScienceRiyadhSaudi Arabia

Personalised recommendations